SCIENCE AT THE SPEED OF BUSINESS

Our fundamental premise is that innovative methods, analytical rigor, and scientific acumen can be provided in a commercial entity that operates “at the speed of business.” Monument Analytics delivers.

Unparalleled Knowledge Base

One of the most remarkable features of Monument Analytics is its access to consultants with an unparalleled knowledge base. Through its independent consulting services, Monument Analytics leverages this acumen to assist clients developing products and services for the benefit of society.

Top Notch Evidence

By capitalizing on this unparalleled depth and breadth of human capital, Monument Analytics is able to generate the highest quality evidence regarding the safety, effectiveness, and real-world value of the full range of medical processes and technologies; and to use this knowledge to help our clients navigate evermore complex and challenging regulatory and payment environments.

Internationally Renowned Experts

Our Principals and Consultants are internationally renowned for their expertise in areas ranging from epidemiology and biostatistics to clinical fields such as cardiovascular medicine, oncology, and immunology.

G. Caleb Alexander
G. Caleb AlexanderMD, MS
CO-FOUNDER & PRINCIPAL
Jonothan C. Tierce
Jonothan C. TierceCPhil
CO-FOUNDER & PRINCIPAL
William V. Padula
William V. PadulaPhD
PRINCIPAL
Natalie Reid
Natalie ReidPhD, MPH, MBA
DIRECTOR
MEET THE CONSULTING TEAM

Services

Our services are broadly organized into four core capabilities

  • Comparative effectiveness analyses
  • Pharmacovigilance and safety assessments
  • Investigations of drug utilization
  • Risk-benefit appraisals
  • Bayesian, meta-analytic and systematic reviews
  • Patient and clinician preferences
  • Global marketplace and pharmaceutical policy
  • Design and conduct of sophisticated comparative effectiveness, pharmacovigilance, and drug utilization studies
  • Advanced techniques for causal inference, management of missing data, and other statistical analysis
  • Cost-benefit analysis and cost-effectiveness analysis
  • Natural history of disease and resource utilization
  • Systematic economic and quality-of-life reviews
  • Core value dossiers

MA in the News

Sept 1, 2021  Caleb Alexander
Monument Analytics Co-Founder and Principal Dr. Caleb Alexander was cited for his expert testimony for plaintiffs in opioid litigation, his perspective of the opioid epidemic, and the appropriate use of effective opioid analgesics in Bloomberg Wealth. The article mentioning Dr. Alexander is titled “Sacklers to Exit From Complex Purdue Bankruptcy With Billions.”

August 11, 2021  Caleb Alexander
Dr. Caleb Alexander, Monument Analytics Co-Founder and Principal, was identified as a possible candidate for FDA commissioner in the opinion piece, “Opinion: Plenty of qualified people are ready to run the FDA. Time for Biden to choose one.”

August 5, 2021
Monument Team: William V. Padula, Natalie M. Reid, Benjamin G. Cohen, Francine Chingcuanco, Jeromie Ballreich, Jonothan Tierce and G. Caleb Alexander
Monument Analytics team members co-authored a Journal of Medical Economics article titled: “Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis.” The cost-effectiveness analysis determined that vaccines have a high probability of reducing healthcare costs and increasing quality-adjusted life years compared to doing nothing.

July 27, 2021  Caleb Alexander
Monument Analytics Co-Founder and Principal Dr. Caleb Alexander was quoted in a Pharmacy Practice News article titled: “7 Habits of Effective COVID-19 Rx Managers.” Dr. Alexander explained the importance of staying up-to-date with treatment guidelines and provided recommendations to stay current with the evolving treatment landscape.

July 23, 2021  Caleb Alexander
Monument Analytics Co-Founder and Principal Dr. Caleb Alexander was interviewed on HealthDay Now in a segment called: “Experts Weigh In On Alzheimer’s Drug Controversy” about the controversial approval of aducanumab. Dr. Alexander’s interview received additional attention in the HealthDay news article titled: “FDA Panel Advisor Who Panned New Alzheimer’s Drug Speaks Out.”

SEE ALL MA NEWS